Brought to you by 
NeoSan gets US rights to Lilly's Darvon and Darvocet N
07 Dec 2022
Executive Summary
AaiPharma's commercialization unit NeoSan Pharmaceuticals acquired US rights to Eli Lilly's Darvon (propoxyphene hydrochloride) and Darvocet N (propoxyphene napsylate with acetaminophen) line of pain management products.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeoSan gets US rights to Lilly's Darvon and Darvocet N
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice